Published in Infect Immun on February 01, 1986
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun (1987) 2.63
Antibody immunity and invasive fungal infections. Infect Immun (1995) 2.31
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med (1991) 2.11
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect Immun (1988) 2.05
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun (1990) 1.89
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun (1991) 1.80
Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun (1990) 1.70
Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines. Infect Immun (1990) 1.62
Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin Exp Immunol (1989) 1.55
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother (1994) 1.48
Antifungal activity of a human antiglucuronoxylomannan antibody. Clin Diagn Lab Immunol (1998) 1.16
Natural killer cells mediate protection induced by a Salmonella aroA mutant. Infect Immun (1992) 1.15
A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect Immun (1997) 1.14
Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization. Infect Immun (1992) 1.10
Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe (2012) 1.07
Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob Agents Chemother (1995) 1.00
Heat shock protein 70 (hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. Clin Exp Immunol (1999) 0.97
The interleukins in acquired disease. Clin Exp Immunol (1988) 0.96
Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J Immunol (2012) 0.90
Expression of antibodies directed to Paracoccidioides brasiliensis glycosphingolipids during the course of paracoccidioidomycosis treatment. Clin Vaccine Immunol (2006) 0.89
Natural killer cells and antifungal host response. Clin Vaccine Immunol (2013) 0.88
Adaptive immunity to fungi. Cold Spring Harb Perspect Med (2014) 0.80
A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol (1981) 8.17
Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med (1974) 6.75
Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol (1982) 3.92
Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun (1984) 2.30
In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol (1982) 2.19
Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect Immun (1976) 2.16
The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol (1979) 2.11
The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol (1979) 2.02
Antibody-dependent killing of Cryptococcus neopormans by human peripheral blood mononuclear cells. Nature (1974) 1.97
Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J Immunol (1967) 1.87
Serodiagnosis of clinical cryptococcosis. Am Rev Respir Dis (1968) 1.76
Morphological characterization of a cell population responsible for natural killer activity. Immunology (1981) 1.73
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect Immun (1981) 1.68
Passive immunization in murine cryptococcosis. Sabouraudia (1981) 1.59
Natural killer cells may be the only cells in normal mouse lymphoid cell populations endowed with cytolytic ability for antibody-coated tumour target cells. Scand J Immunol (1978) 1.58
Fc receptors on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1977) 1.53
Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities. J Immunol (1982) 1.51
Antibody-dependent leukocyte killing of Cryptococcus neoformans. J Immunol (1983) 1.47
In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect Immun (1985) 1.30
Influence of agglutinating antibody in experimental cryptococcal meningitis. Br J Exp Pathol (1981) 1.29
Characterization of human K cells by surface antigens and morphology at the single cell level. J Immunol (1983) 0.90
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 6.88
Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci U S A (1991) 4.48
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med (1995) 3.18
A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A (1996) 3.07
A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science (1990) 2.83
Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun (1979) 2.76
Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol (1982) 2.36
Capsule size of Cryptococcus neoformans: control and relationship to virulence. Infect Immun (1977) 2.35
In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol (1982) 2.19
What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis (1998) 2.18
Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci U S A (1993) 2.03
Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun (1991) 1.90
Host-etiological agent interactions in intranasally and intraperitoneally induced Cryptococcosis in mice. Infect Immun (1980) 1.88
Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun (1980) 1.77
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1993) 1.72
WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. J Thromb Haemost (2010) 1.69
Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol (1999) 1.69
Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1993) 1.57
Skin testing of guinea pigs and footpad testing of mice with a new antigen for detecting delayed hypersensitivity to Cryptococcus neoformans. Infect Immun (1974) 1.56
Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells. J Immunol (1983) 1.52
Stimulated renal tubular epithelial cells induce anergy in CD4+ T cells. Kidney Int (1993) 1.50
Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect Immun (1991) 1.48
Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2). J Immunol (1985) 1.48
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med (1995) 1.45
Natural cellular resistance of beige mice against Cryptococcus neoformans. J Immunol (1986) 1.44
Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase. Cell (1990) 1.44
Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells. Infect Immun (1986) 1.41
Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun (1997) 1.41
Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun (1995) 1.41
Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s). Infect Immun (1987) 1.39
Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect Immun (1999) 1.35
Uncompensated care by hospitals or public insurance for the poor. Does it make a difference? N Engl J Med (1986) 1.35
Effects of first-order Cryptococcus-specific T-suppressor cells on induction of cells responsible for delayed-type hypersensitivity. Infect Immun (1985) 1.34
Induction and expression of cell-mediated immune responses in inbred mice infected with Coccidioides immitis. Infect Immun (1988) 1.33
Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosis. Infect Immun (1979) 1.32
Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun (1995) 1.31
In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect Immun (1985) 1.30
A child with partial deletion of a G-group autosome. Am J Dis Child (1967) 1.27
Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity (1995) 1.26
Structural mutation affecting intracellular transport and cell surface expression of murine class II molecules. J Exp Med (1988) 1.26
Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J Clin Invest (1996) 1.24
The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther (1999) 1.23
Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol (1989) 1.17
Murine natural killer cell interactions with a fungal target, Cryptococcus neoformans. Infect Immun (1989) 1.17
Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol (2000) 1.16
Blockade of CD86 ameliorates Leishmania major infection by down-regulating the Th2 response. J Infect Dis (1996) 1.14
Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen. Infect Immun (1993) 1.11
Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. J Immunol (1994) 1.08
In vitro effects of natural killer cells against Paracoccidioides brasiliensis yeast phase. Infect Immun (1984) 1.07
Responses of murine natural killer cells to binding of the fungal target Cryptococcus neoformans. Infect Immun (1991) 1.06
Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1990) 1.05
Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med Mycol (1998) 1.04
T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection. J Infect Dis (1989) 1.04
Musculoskeletal responses to high- and low-intensity resistance training in early postmenopausal women. Med Sci Sports Exerc (2000) 1.03
In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity (1994) 1.03
Immunoadsorption of Cryptococcus-specific suppressor T-cell factors. Infect Immun (1986) 1.03
Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1994) 1.03
A functional role for signal transduction via the cytoplasmic domains of MHC class II proteins. J Immunol (1989) 1.02
Cytoplasmic components of natural killer cells limit the growth of Cryptococcus neoformans. J Leukoc Biol (1990) 1.01
Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction. Immunology (1997) 1.01
Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation. Infect Immun (1989) 0.99
The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice. Infect Immun (2000) 0.99
Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans. Infect Immun (1991) 0.99
MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol (1997) 0.98
Induction of antigen-specific T suppressor cells by soluble Paracoccidioides brasiliensis antigen. Infect Immun (1988) 0.98
Immunoglobulin isotype regulation by antigen-presenting cells in vivo. Eur J Immunol (1994) 0.97
In vitro interactions of immune lymphocytes and Cryptococcus neoformans. Infect Immun (1982) 0.95
Characterization of an in vitro-stimulated, Cryptococcus neoformans-specific second-order suppressor T cell and its precursor. Infect Immun (1988) 0.95
Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol (1996) 0.92
Direct antimicrobial activity of T cells. Immunol Today (1995) 0.92
Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice. Infect Immun (1995) 0.91
Casein expression in cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 0.91
Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. Infect Immun (1997) 0.91
Expression and functional analysis of murine B7 delineated by a novel monoclonal antibody. Cell Immunol (1994) 0.91
K562 cell strains differ in their response to poliovirus infection. Virology (1995) 0.91
Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J Immunol (1994) 0.90
Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia (1999) 0.90
CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect Immun (2000) 0.89
Cytoplasmic domain affects membrane expression and function of an Ia molecule. Proc Natl Acad Sci U S A (1988) 0.89
Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes. Infect Immun (1995) 0.89
Differential induction of class II gene expression in murine pre-B-cell lines by B-cell stimulatory factor-1 and by antibodies to B-cell surface antigens. J Mol Cell Immunol (1988) 0.87
Characterization of efferent T suppressor cells induced by Paracoccidioides brasiliensis-specific afferent T suppressor cells. Infect Immun (1988) 0.87
Effects of Cryptococcus neoformans-specific suppressor T cells on the amplified anticryptococcal delayed-type hypersensitivity response. Infect Immun (1991) 0.85
Intestinal secretion of digoxin in the rat. Augmentation by feeding activated charcoal. Naunyn Schmiedebergs Arch Pharmacol (1980) 0.85
Mechanisms for induction of L-selectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan. Infect Immun (1999) 0.84
Role of the C-C chemokine, TCA3, in the protective anticryptococcal cell-mediated immune response. J Immunol (1999) 0.84
Immunomodulation in the mycoses. J Med Vet Mycol (1992) 0.82
Intracardiac repair for anomalous pulmonary venous connection of right lung to inferior vena cava. Ann Thorac Surg (1971) 0.81
Mechanisms of cell-mediated immunity in fungal infection. J Med Vet Mycol (1994) 0.80
Deep seated giant arteriovenous malformations in infancy. Surg Neurol (1978) 0.77
Tolerability and anti-inflammatory effects of glucuronoxylomannan in collagen-induced arthritis. Scand J Immunol (2004) 0.77
IFN-gamma and b7 as costimulators of antitumor immune-responses. Int J Oncol (1995) 0.77
Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol (1996) 0.77
Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res (1997) 0.76
Use of the prolene hernia system for inguinal hernia repair: retrospective, comparative time analysis versus other inguinal hernia repair systems. Am Surg (2001) 0.76